Table 2.
Clinical and biopsy characteristics.
| Overall | Centre 1 | Centre 2 | Centre 3 | |
|---|---|---|---|---|
| No. of patients | 446 | 142 (31.8) | 198 (44.4) | 106 (23.8) |
| Age (yr), median (IQR) | 65 (60–70) | 64 (59–69) | 65 (60–68) | 68 (64–73) |
| PSA (ng/ml), median (IQR) | 7.1 (5.3–9.7) | 7.5 (5.4–10.5) | 6.6 (4.9–8.6) | 8.0 (6.1–10.2) |
| DRE, n (%) | ||||
| Unknown status | 101 (22.6) | 82 (57.7) | 19 (9.6) | 0 (0) |
| cT1 | 262 (58.7) | 38 (26.8) | 157 (79.3) | 67 (63.2) |
| cT2 | 74 (16.6) | 18 (12.7) | 20 (10.1) | 36 (34.0) |
| cT3 | 9 (2.1) | 4 (2.8) | 2 (1.0) | 3 (2.8) |
| Biopsy status, n (%) | ||||
| Biopsy naïve | 346 (77.6) | 95 (66.9) | 177 (89.4) | 74 (69.8) |
| Previous negative biopsy | 37 (8.3) | 18 (12.7) | 7 (3.5) | 12 (11.3) |
| Previous prostate cancer diagnosis | 63 (14.1) | 29 (20.4) | 14 (7.1) | 20 (18.9) |
| MRI prostate volume (cc), median (IQR) | 48.6 (37.0–67.8) | 50 (37–72) | 49 (35–71) | 48 (39–63) |
| Maximum PI-RADS, n (%) | ||||
| 1–2 | 102 (22.9) | 28 (19.7) | 61 (30.8) | 13 (12.3) |
| 3 | 97 (21.7) | 16 (11.3) | 61 (30.8) | 20 (18.9) |
| ≥4 | 247 (55.4) | 98 (69.0) | 76 (38.4) | 73 (68.8) |
| Days between mpMRI and biopsy, median (IQR) | 25 (10–42) | 19.5 (7–39) | 25 (11–42) | 34 (16–47) |
| Biopsy technique, n (%) | ||||
| TRUS (systematic only) | 67 (15.0) | 15 (10.6) | 45 (22.7) | 7 (6.6) |
| TRUS cognitive fusion | 187 (41.9) | 88 (62.0) | 62 (31.3) | 37 (34.9) |
| TRUS software fusion | 10 (2.2) | 4 (2.8) | 6 (3.1) | 0 (0) |
| Transperineal (systematic only) | 26 (5.8) | 3 (2.1) | 19 (9.6) | 4 (3.8) |
| Transperineal cognitive fusion | 54 (12.2) | 6 (4.2) | 1 (0.5) | 47 (44.3) |
| Transperineal software fusion | 102 (22.9) | 26 (18.3) | 65 (32.8) | 11 (10.4) |
| Highest-grade group cancer detected, n (%) | ||||
| No cancer | 130 (29.2) | 40 (28.2) | 71 (35.9) | 19 (17.9) |
| Grade group 1 | 84 (18.8) | 23 (16.2) | 39 (19.7) | 22 (20.8) |
| Grade group 2 | 89 (20.0) | 37 (26.1) | 29 (14.7) | 23 (21.7) |
| Grade group 3 | 71 (15.9) | 20 (14.1) | 29 (14.7) | 22 (20.8) |
| Grade group ≥4 | 72 (16.1) | 22 (15.4) | 16 (8.0) | 20 (18.8) |
| Cores taken at biopsy, median (IQR) | 22 (16–30) | 18 (14–27) | 22 (18–28) | 27 (20–35) |
DRE = digital rectal examination; IQR = interquartile range; mpMRI = multiparametric magnetic resonance imaging; MRI = magnetic resonance imaging; PI-RADS = Prostate Imaging Reporting and Data System; PSA = prostate-specific antigen; TRUS = transrectal ultrasound.